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Introduction
• Gaucher disease (GD), a lysosomal storage disease, is a genetic 
disorder that causes glucocerebrosidase (GCase) to be unable to 
function correctly.
• GCase breaks down glucocerebroside (GluCer) and in GD, a 
buildup of  GluCer, often leads to neuropathic conditions
• Common treatment is enzyme replacement therapy, the intravenous 
delivery of  recombinant enzymes5
• Enzyme replacement therapy has an inability to treat the central 
nervous system because of  its inability to cross the blood-brain 
barrier (BBB)
• In vitro studies with Gaucher afflicted BBB cellular systems are 
needed to test delivery of  novel recombinant enzymes
• Severely limited by scarcity and expense of  Gaucher endothelial 
cells, astrocytes, and neurons, which compose the BBB.
• Can potentially use inhibitors to lower GCase activity levels in
healthy cells1,2,3
• Inhibitors should not affect cell health and should sustain lowered 
activity level4,6
Results Conclusions
• Treatment with CBE lowered GCase activity and 
increased GluCer accumulation in both HBMEC and 
astrocyte cell types.
• An in vitro model of  the Gaucher BBB was established 
using CBE treated HBMEC and astrocytes with iPS 
derived Gaucher neurons
• Transport of  modified GCase, modified to transcytose
more efficiently, was effectively tested on Gaucher 
BBB trans well model
• More efficient transcytosis was observed with 
modified GCase with a higher accumulation of  control 
GCase in BBB and a higher accumulation of  modified 
GCase in neurons.
• High colocalization with lysosomes, primary 
destination of  GCase, was seen with modified GCase 
in iPS derived Gaucher neurons, and it was also 
effective at lowering lysosomal size.
• No significant effect on cell viability was exhibited 
with treatment of  modified GCase in iPS derived 
Gaucher neurons.
• Overall model provides a promising step towards 
testing potential therapeutics for Gaucher disease.
• Future work can include testing GluCer clearance of  
modified GCase in neurons
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Goal
• Develop a BBB pharmacological model of Gaucher disease
involving treating healthy endothelial cells, astrocytes, to exhibit
Gaucher phenotype, and iPS derived Gaucher neurons and test
modified GCase (modified to transcytose BBB) on the model for
delivery
Methodology
• Cell culture techniques were used to grow healthy human brain 
macrovascular endothelial cells (HBMECs) and astrocytes and both 
lines were treated with conduritol beta-epoxide (CBE), an inhibitor of  
GCase
• Verification of  Gaucher phenotype was achieved through 
immunofluorescence analysis of  fluorescent GluCer treatment of  
cells after CBE treatment 
• Gaucher phenotype also verified through enzymatic activity assays 
of  cell lysates
• BBB model was built through a trans well system with CBE treated 
HBMEC on apical side, astrocytes on basal side of  filter, and iPS 
derived Gaucher neurons in the basal well
• Immunofluorescence studies was used to analyze transcytosis of  
modified GCase in trans well and iPS derived Gaucher neurons
• Cells often treated with TNF-⍺, an inflammatory cytokine, to mimic 
inflammatory response state. Inflammation plays a key role in 
pathogenesis of  Gaucher disease.
• Enzymes were radiolabeled with iodine-125, applied to the apical 
side of  the trans well system for 1h, 3h, 5h or 24h following which the 
cells on the filter and the neurons were collected and radioactive 
cpms were determined.
I. HBMECs and Astrocytes treated with CBE 
showed significantly decreased GCase Activity
Figure 1: 
Diagram of  
the Blood-
Brain Barrier
Figure 2: Enzyme activity assays on pharmacological models of  HBMECs and astrocytes. HBMEC and astrocytes 
were incubated overnight with TNF-⍺ at 10 ng/mL and CBE at 200 µM. Cells were then lysed for protein extraction. 
Amount of  protein in lysates was quantified by BCA. Cell lysates were incubated for 30 min at 37 C with 
fluorescent 4-Methylumbelliferyl-β-D-glycopyranoside, which is a substrate for GCase. Amount of  substrate 
cleaved was quantified by measuring fluorescence of  samples with microplate spectrophotometer. Cells not 
treated with either TNF-⍺ or CBE were controls. (Left) Enzymatic activity in pmol substrate cleaved per minute per 
µg of  protein in HBMEC lysates. (Right) Enzymatic activity in pmol substrate cleaved per minute per µg of  protein 
in astrocyte lysates. Data are mean±SEM (N=2). Significance level of  p=0.05.
II. HBMECs and Astrocytes treated with CBE 







Figure 3: Lipid accumulation assay on pharmacological models of  HBMECs and astrocytes. HBMEC and 
astrocytes were incubated overnight with TNF-⍺ at 10 ng/mL. Cells were incubated with CBE for 72 h at 200 µM. 
Fluorescent lipid N-hexanoyl-NBD-Glucosylceramide, the substrate for GCase which accumulates in this 
disease, was added to cells at 5 µg per well for 48 hr. The level of  fluorescent GluCer was visualized and 
quantified by microscopy and using ImagePro Analyzer. Cells without CBE and TNF treatment were controls. (A) 
Microscope visualization of  HBMEC at 60X magnification. Green is GluCer. Blue is nuclei. (B) Microscope 
visualization of  astrocytes at 60X magnification. Green is GluCer. Blue is nuclei. (C) Mean intensity of  
fluorescence in HBMEC. (D) Mean intensity of  fluorescence in astrocytes. Data are mean±SEM (N=2).
III. Modified GCase transcytoses across Gaucher BBB trans well model 
more efficiently while GCase accumulates in model  
A B
WT Untreated GD2 Untreated GD2 Modified GCase GD-2 GCase
Figure 4: Transport and effect of glucocerbrosidase enzymes across the Gaucher BBB model. A BBB model of
Gaucher disease was created by culturing cells on a trans well. HBMEC were grown on apical side of filter, and
astrocytes on basal side. Both lines were treated with CBE at 200 µM and TNF-⍺ at 10 ng/mL. iPS derived Gaucher
neurons were grown on bottom basal well. Cells were treated with modified GCase or control Gcase radiolabeled
with Iodine-125 at 3.4 µg/well. Wildtype neurons with no treatment was also included as a control. Cells were also
treated with lysotracker to visualize lysosomes, where smaller lysosomes indicated a rescue of cells, and
fluorescent anti-GCase antibody to visualize GCase delivery. (A) Microscope visualization of WT and iPS derived
Gaucher neurons at 60X. Green is protein. Red is lysotracker (lysosomes). Blue is nuclei. (B) Molecule (protein)
count determined from the radioactive cpms in BBB over time (C) Molecule (protein) count in iPS derived
Gaucher neurons over time.
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IV. Modified GCase shows high colocalization with 




E Figure 5: Lysosomal colocalization study of  modified GCase in iPS derived neurons. iPS derived Gaucher neurons were 
treated with TNF-⍺ at 10 ng/mL and were treated with modified GCase at 3.4 µg/well, with treatment incubations of  2h, 5h, and 
24h. Cells were then treated with anti-GCase and LAMP-1 antibodies for protein and lysosomal staining respectively. Level of  
protein accumulation and colocalization with lysosomes was visualized and quantified using microscopy. Untreated neurons 
were control. (A) Microscope visualization of  iPS derived Gaucher neurons at 60X. Green is protein. Red is lysosomes. Yellow 
is colocalized protein. Blue is nuclei. (B) Lysosomal colocalization of  modified GCase based on fluorescent object count. (C) 
Lysosomal colocalization of  modified GCase based on area of  fluorescence. (D) Total protein count versus protein 
colocalized with lysosomes count. (E) Total protein fluorescent area versus protein colocalized with lysosomes fluorescent 
area. Data are mean±SEM (N=2)
2h Treatment 5h Treatment 24h Treatment Untreated
V. Modified GCase shows no significant increase 
of  cytotoxicity in iPS derived Gaucher neurons
Figure 6: Toxicity study of  modified GCase enzyme in iPS derived neurons. iPS derived Gaucher neurons and 
Wildtype neurons were untreated, treated with 10 µg of  modified GCase for 48 h, or hydrogen peroxide for 48 h. 
After incubation with treatments or lack of  treatment, calcein AM and EthD-1 were used to stain cells green if  live, 
or red if  dead respectively. Number of  live cells, dead cells, and thus viability was visualized and quantified by 
microscopy. Wildtype untreated was the positive control while hydrogen peroxide treated GD2 was the negative 
control. (Left) % Viability of  each condition. (Right) Microscope visualization of  neurons at 20X. Green is live cell. 
Red is dead cell. Data are mean±SEM (N=3)
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